Pangaea Oncology（PANG）株式概要医療サービス会社であるパンゲア・オンコロジー社（Pangaea Oncology, S.A.）は、スペインおよびその他の欧州連合加盟国のがん患者にさまざまなサービスを提供している。 詳細PANG ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長4/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より0.4%で取引されている 収益は年間120.71%増加すると予測されています リスク分析意味のある時価総額がありません ( €57M )すべてのリスクチェックを見るPANG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.588.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-5m27m2016201920222025202620282031Revenue €26.8mEarnings €3.4mAdvancedSet Fair ValueView all narrativesPangaea Oncology, S.A. 競合他社EuroespesSymbol: BME:EEPMarket cap: €3.7mLabiana HealthSymbol: BME:LABMarket cap: €52.9mFabtech TechnologiesSymbol: NSEI:FABTECHMarket cap: ₹6.5bTelescope InnovationsSymbol: CNSX:TELIMarket cap: CA$69.5m価格と性能株価の高値、安値、推移の概要Pangaea Oncology過去の株価現在の株価€1.5852週高値€1.7552週安値€1.51ベータ0.00501ヶ月の変化0.64%3ヶ月変化-7.06%1年変化-7.06%3年間の変化-27.52%5年間の変化-21.00%IPOからの変化-44.17%最新ニュースお知らせ • May 28Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026.Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.7% to €1.75. The fair value is estimated to be €1.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 122% over the last year. Earnings per share has declined by 102%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.New Risk • Nov 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€404k net loss in 3 years). Market cap is less than US$100m (€58.4m market cap, or US$67.3m).Breakeven Date Change • Sep 11Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 14Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 20Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.最新情報をもっと見るRecent updatesお知らせ • May 28Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026.Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.7% to €1.75. The fair value is estimated to be €1.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 122% over the last year. Earnings per share has declined by 102%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.New Risk • Nov 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€404k net loss in 3 years). Market cap is less than US$100m (€58.4m market cap, or US$67.3m).Breakeven Date Change • Sep 11Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 14Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 20Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.New Risk • Jun 05New major risk - Revenue and earnings growthEarnings have declined by 7.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€58.4m market cap, or US$66.8m).お知らせ • Jun 04Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025.New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€502k net loss in 2 years). Market cap is less than US$100m (€59.4m market cap, or US$66.3m).Breakeven Date Change • Apr 24No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.New Risk • Sep 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€200k net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (€59.3m market cap, or US$65.4m).お知らせ • Jun 05Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024.Reported Earnings • May 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €9.95m (up 49% from FY 2022). Net loss: €4.66m (loss widened 72% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.分析記事 • Nov 09Is Pangaea Oncology (BME:PANG) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Nov 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €2.7m Forecast net loss in 1 year: €600k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€600k net loss next year). Market cap is less than US$100m (€58.5m market cap, or US$62.8m).Breakeven Date Change • Nov 03Forecast to breakeven in 2024The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests losses will reduce by 78% to 2023. The company is expected to make a profit of €900.0k in 2024. Average annual earnings growth of 99% is required to achieve expected profit on schedule.New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.0% average weekly change). Market cap is less than US$100m (€58.5m market cap, or US$62.1m).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Breakeven Date Change • Apr 01Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 111% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 91% is required to achieve expected profit on schedule.分析記事 • May 17Pangaea Oncology, S.A.'s (BME:PANG) About To Shift From Loss To ProfitWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...Is New 90 Day High Low • Feb 11New 90-day low: €1.42The company is down 12% from its price of €1.62 on 13 November 2020. The Spanish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 10.0% over the same period.分析記事 • Feb 01Analysts Expect Pangaea Oncology, S.A. (BME:PANG) To Breakeven SoonWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...Is New 90 Day High Low • Jan 07New 90-day low: €1.44The company is down 3.0% from its price of €1.49 on 09 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.お知らせ • Oct 15Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million.Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million on October 13, 2020. Under the terms of transaction, Vidaro Inversiones purchased a total of 1.11 million securities of Pangaea Oncology at price of €1.36 for each Pangea share. Vidaro Inversiones S.L. completed the acquisition of 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL on October 13, 2020.Is New 90 Day High Low • Oct 14New 90-day high: €1.54The company is up 3.0% from its price of €1.49 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 14% over the same period.株主還元PANGES Life SciencesES 市場7D0%-0.5%0.4%1Y-7.1%-7.5%23.8%株主還元を見る業界別リターン: PANG過去 1 年間で-7.5 % のリターンをもたらしたSpanish Life Sciences業界と一致しました。リターン対市場: PANGは、過去 1 年間で23.8 % のリターンを上げたSpanish市場を下回りました。価格変動Is PANG's price volatile compared to industry and market?PANG volatilityPANG Average Weekly Movement3.7%Life Sciences Industry Average Movement7.2%Market Average Movement3.6%10% most volatile stocks in ES Market6.7%10% least volatile stocks in ES Market0.9%安定した株価: PANG 、 Spanish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: PANGの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006165Javier Rivela-Rodriguezwww.panoncology.com医療サービス会社であるPangaea Oncology, S.A.は、スペインおよび欧州連合諸国のがん患者に様々なサービスを提供している。同社は、腫瘍組織や血液中の変異解析、遺伝子増幅・転座検査、免疫組織化学、遺伝子発現などの分子診断、臨床試験、MTT増殖アッセイ、ウェスタンブロッティング、コロニー形成・遊走・浸潤アッセイ、遺伝子サイレンシングなどのin vitro薬剤プロファイリング、コンパニオン診断プラットフォームの検証、市販プラットフォームとの比較検証、診断薬企業のためのアドホックR+Dを行うDxプラットフォームなどを提供している。また、前臨床開発中の標的治療薬の新規ターゲットを同定するバイオマーカー探索も行っている。パンゲア・オンコロジー社は2006年に設立され、スペインのバルセロナを拠点としている。もっと見るPangaea Oncology, S.A. 基礎のまとめPangaea Oncology の収益と売上を時価総額と比較するとどうか。PANG 基礎統計学時価総額€56.74m収益（TTM）-€3.60m売上高(TTM)€16.73m3.4xP/Sレシオ-15.8xPER（株価収益率PANG は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PANG 損益計算書（TTM）収益€16.73m売上原価€2.58m売上総利益€14.15mその他の費用€17.75m収益-€3.60m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.10グロス・マージン84.56%純利益率-21.49%有利子負債／自己資本比率21.4%PANG の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/08 09:12終値2026/06/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pangaea Oncology, S.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alfredo Echevarria OteguiLighthouse-IEAF Servicios de Analisis
お知らせ • May 28Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026.
Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.7% to €1.75. The fair value is estimated to be €1.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 122% over the last year. Earnings per share has declined by 102%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.
New Risk • Nov 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€404k net loss in 3 years). Market cap is less than US$100m (€58.4m market cap, or US$67.3m).
Breakeven Date Change • Sep 11Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 14Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 20Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
お知らせ • May 28Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026.
Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.7% to €1.75. The fair value is estimated to be €1.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 122% over the last year. Earnings per share has declined by 102%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.
New Risk • Nov 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€404k net loss in 3 years). Market cap is less than US$100m (€58.4m market cap, or US$67.3m).
Breakeven Date Change • Sep 11Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 14Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 20Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
New Risk • Jun 05New major risk - Revenue and earnings growthEarnings have declined by 7.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€58.4m market cap, or US$66.8m).
お知らせ • Jun 04Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025.
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€502k net loss in 2 years). Market cap is less than US$100m (€59.4m market cap, or US$66.3m).
Breakeven Date Change • Apr 24No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.
Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.
New Risk • Sep 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€200k net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (€59.3m market cap, or US$65.4m).
お知らせ • Jun 05Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024.
Reported Earnings • May 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €9.95m (up 49% from FY 2022). Net loss: €4.66m (loss widened 72% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
分析記事 • Nov 09Is Pangaea Oncology (BME:PANG) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Nov 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €2.7m Forecast net loss in 1 year: €600k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€600k net loss next year). Market cap is less than US$100m (€58.5m market cap, or US$62.8m).
Breakeven Date Change • Nov 03Forecast to breakeven in 2024The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests losses will reduce by 78% to 2023. The company is expected to make a profit of €900.0k in 2024. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.0% average weekly change). Market cap is less than US$100m (€58.5m market cap, or US$62.1m).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Breakeven Date Change • Apr 01Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 111% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 91% is required to achieve expected profit on schedule.
分析記事 • May 17Pangaea Oncology, S.A.'s (BME:PANG) About To Shift From Loss To ProfitWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...
Is New 90 Day High Low • Feb 11New 90-day low: €1.42The company is down 12% from its price of €1.62 on 13 November 2020. The Spanish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 10.0% over the same period.
分析記事 • Feb 01Analysts Expect Pangaea Oncology, S.A. (BME:PANG) To Breakeven SoonWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...
Is New 90 Day High Low • Jan 07New 90-day low: €1.44The company is down 3.0% from its price of €1.49 on 09 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.
お知らせ • Oct 15Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million.Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million on October 13, 2020. Under the terms of transaction, Vidaro Inversiones purchased a total of 1.11 million securities of Pangaea Oncology at price of €1.36 for each Pangea share. Vidaro Inversiones S.L. completed the acquisition of 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL on October 13, 2020.
Is New 90 Day High Low • Oct 14New 90-day high: €1.54The company is up 3.0% from its price of €1.49 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 14% over the same period.
